Compare TEVA & AMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | AMP |
|---|---|---|
| Founded | 1901 | 1894 |
| Country | Israel | United States |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 39.6B |
| IPO Year | N/A | 2009 |
| Metric | TEVA | AMP |
|---|---|---|
| Price | $32.98 | $470.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $38.63 | ★ $544.91 |
| AVG Volume (30 Days) | ★ 4.7M | 563.0K |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | N/A | ★ 9.77 |
| EPS | N/A | ★ 9.68 |
| Revenue | N/A | ★ $18,911,000,000.00 |
| Revenue This Year | N/A | $1.79 |
| Revenue Next Year | $2.97 | $4.20 |
| P/E Ratio | ★ $28.19 | $47.51 |
| Revenue Growth | N/A | ★ 5.49 |
| 52 Week Low | $14.99 | $422.37 |
| 52 Week High | $37.35 | $550.18 |
| Indicator | TEVA | AMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 61.44 |
| Support Level | $30.53 | $450.43 |
| Resistance Level | $35.37 | $474.78 |
| Average True Range (ATR) | 1.15 | 10.06 |
| MACD | -0.14 | 2.23 |
| Stochastic Oscillator | 18.99 | 90.47 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.